Teva rises on FDA approval for generic obesity drug

** U.S.-listed shares of Israeli drugmaker Teva Pharmaceuticals TEVA.N rise 3.2% to $18.63 premarket

** Co says the US FDA has approved its generic version of Novo Nordisk's NOVOb.CO older weight loss drug Saxenda

** "We will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss"- TEVA

** Saxenda is approved for adults with obesity, who also have weight-related medical problems, and for certain pediatric patients

** Up to last close, TEVA down 25.5% YTD